Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
COIN, filled gap now from a couple weeks ago
"Right now, his interactions are with doctors, clinicians and regulators in gaining acceptance and licensing. From all indications, this is going very well"
I guess you have to talk to him personally to know this. God forbid he address all his shareholders and let them know this.
You took the words right out of my mouth. Doc may very well be doing one hell of a job at executing his business plan but how the hell does anyone know that???? Absolutely zero shareholder communication. You shouldn't have to call the guy personally to find out what he's been doing.
All I can go by is from what I see and what I see is a guy that doesn't know how to manage a publicly traded company. I to am a stucky. I have hung on as well mainly because of the share structure and the possability that maybe Dr. Walker will begin to give a flying fu@k about his shareholders at some point if indeed he is legit.
COIN C'mon bust out a here!
COIN, Tempted to buy more but just not sure of it.
EGT, buy the dip, it's going back up
I shouldn't complain to much, made decent bank on it the past couple spikes but could have done alot better. Held to much on the previous spikes. I will say once this stock based it was real easy to watch the chart and know when it was headed back up.
.48 x .49 f'n suck me sideways. Damn I f'd this one up.
KERX huge bid .158 x .1597 looks strong
EGT down goes .12, breaking out here
EGT it's time to go now, .12's getting smacked, MACD going positive
There it goes, .1299 x .13 breakout
EGT tight here .1199 x .12 gonna go!
No i didn't, what price?
Watch EGT here. Someones been loading the crap out of it contolably IMO. KERX here at .16 might break aswell
Well when the begin to cover, they can take me along for the ride, weeeeeeeeeee!!!!!
EGT .1006 x .1097, I believe theres been a huge buyer eating up these .09 & .10's but controlled so the pps does not get away from him.
KERX, .16 Resistance going down, .165 print
In COIN 1.01 for a pop
In COIN 1.01 for a pop
Looks like NITE dropped back to .195 on the ask. Just have to wipe out ARCA here
Holding up well here to my surprise. Of course it would the time I decide to sell all g-dammit.
EGT .1099 X .11 about to break out here! .11's getting hammered now!
EGT .10 x .11, break of .11 huge IMO
EGT .11 break would be huge don't you think?
EGT, .10 x .11 now. Someones been loading heavy lately
KERX .158 lookin good
Were lucky to be holding where we are considering the new shares there issuing for the 80k capital raise, Wouldn't expect a move up anytime soon.
The problem here is JD has no idea of how to promote his stock to get the pps to a respectable level to where he can dilute gradually when he needs a little extra capital. This has been the major problem all along and is why the pps is where it is IMO. The whole credit crisis has not helped either. It's not that this is a bad company or a scam but to most it looks that way because he hasn't been able to convince the public otherwise. Part of the problem is he probably has to many irons in the fire and trying to do everything himself. Meanwhile, his stock suffers because of it.
Since he hasn't been able to accomplish this he now needs to sell millions more shares at a share price thats in the basement to get a relativly small amount of capital and in most peoples minds when they see dilution at this pps, they throw this stock in with the rest of the junk scam pinkies out there. He's just damn lucky that there appears to be alot of loyals that believe in him and are buying up millions supporting this.
JMHO
EGT big buyer battling big seller the way it looks. Huge smacks at the ask followed buy relentless whacks on the bid.
EGT Nice volume and big blocks going off, looks like she wants to cut loose!
EGT posted on it earlier something was up. Big time buying at the ask lately, boom time
EGT 85k print at the ask of .09 earlier. Somebody is buying the crap out of this lately.
KERX .158 here
KERX .14 trying to turn up after some nice consolidation in the .12's
Level 2 wall at .22 may be fake IMO, chart wise i just don't see any resistance there really
DPDW breaking .17 resistance, should see 20's now
DPDW breaking .17 resistance, should see 20's now
EGT looks to be carving out a bottom in the .08 area. Sure looks like someone is loading up here.
Those financials look pretty sick, that should kill yesterdays run. I was holding a small core here through out these bounces the past few months but yesterday I sold all. Will see what happens
DPDW, already up a good bit but chart looks beautiful for a major breakout
MRNA news, gapper!!!!
NEWS MDRNA Announces Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology
BOTHELL, WA -- (Marketwire) -- 03/23/09 -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into a licensing agreement with Novartis for MDRNA's liposomal technology platform for siRNA delivery. MDRNA will receive $7.25 million in upfront fees for the non-exclusive license. Additionally, the companies have entered into a separate agreement, which provides Novartis with an exclusive period to negotiate a research and development collaboration and broader licensing rights related to MDRNA's RNAi drug delivery platform. Terms of this separate agreement were not disclosed.
"We are pleased to enter into this agreement with Novartis, a global leader in the field of RNAi-based therapeutics," stated J. Michael French, President and Chief Executive Officer of MDRNA. "MDRNA's DiLA2 technology for siRNA delivery is effective and efficient at silencing gene targets in the liver and jejunum. Further, the in vivo tolerability of the DiLA2 technology is excellent. We have not observed any delivery related adverse effects in the liver as measured by typical serum chemistries or any significant increases in cytokine levels, which are hallmarks of cell damage. We view this license as yet another important validation of our siRNA technologies and we look forward to a strong and growing relationship with Novartis."
About the DiLA2 Platform
The DiLA2 Platform is MDRNA's proprietary technology platform for creating novel liposomal delivery systems from amino acids. The DiLA2 Platform enables MDRNA to tailor the charge, linker and acyl chains of amino acids in order to optimize the liposome for delivery to the target tissue of interest. In addition, the DiLA2 Platform is designed to permit attachment of various peptides and other targeting molecules to improve a variety of delivery characteristics. In addition, MDRNA is utilizing peptides for nanoparticle formulations to increase cellular uptake and endosomal release.
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi).
Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches.
These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in key therapeutic areas including oncology, metabolic disorders and inflammation. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies.
We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statement
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of MDRNA or a subsidiary to obtain additional funding; (ii) the ability of MDRNA or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of MDRNA, a subsidiary and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of MDRNA, a subsidiary and/or a partner to obtain required governmental approvals; and (v) the ability of MDRNA, a subsidiary and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in MDRNA's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. MDRNA assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contact:
Matthew D. Haines
Senior Director, Investor Relations and Corporate Communications
(212) 209-3874
Email Contact
McKinney|Chicago (Media)
Did you ask him wtf he hired them in the first place for and what it cost him(us) for absolutley no service whatsoever???